Periventricular Nodular Heterotopias (PVNH)


Periventricular nodular heterotopia (PVNH), also known as subependymal grey matter heterotopia, is a brain malformation of cortical development. PVNH is characterized by an abnormal clumping of grey matter (nerve cells) around the deep fluid chambers inside the brain called the ventricles. The name reflects these findings: Periventricular (around the ventricles) nodular (clumps) heterotropia (out of place).

During early brain development, when the baby is still in the womb, normal cells migrate from a location beside the ventricle to the surface of the brain. In PVNH, a small portion of these cells fail to migrate and stay as clumps around the ventricles.

Periventricular nodular heterotopias are among the most common types of abnormal brain formation encountered in clinical practice. People with this abnormality frequently present with focal epilepsy that can be a drug-resistant (fail to respond to seizure medication). A variable degree of intellectual disability can be seen. PVNH can also occur in conjunction with Ehlers-Danlos syndrome, a condition that affects the body’s connective tissues.

Most individuals with PVNH are female and have epilepsy as their sole comorbid condition. PVNH, while less common in males, is thought to affect males more severely, and may present with epilepsy, intellectual disability, and other congenital anomalies.

These abnormal cells commonly result in seizures - up to 80-100% of people with this abnormality will have periventricular nodular heterotopia epilepsy and seizures.

  • Both focal seizures and generalized tonic-clonic seizures can be seen in patients with PVNH.
  • Additionally, seizures may start on one side (unilateral) and can spread to involve both sides of the brain (bilateral) and become a generalized seizure.
    • Bilateral periventricular nodular heterotopia (lining lateral ventricles) is the most common form of grey matter heterotopia.
  • The type of seizures seen in patients with PVNH depend on the location of these clumps and in the involved brain region (temporal lobe, frontal lobe, parietal lobe etc.).

PVNH can be inherited from an affected parent or can be seen de novo, meaning that the genetic change is occurring for the first time in the affected person and is not present in either parent. The genetic abnormality involves genes that are responsible for regulating the migration of nerve cells. Genetic factors play a role in some cases of bilateral heterotopia.

  • The most common genetic variant involves the Filamin A (FLNA) gene which builds the protein that helps with cell shape. This gene is located on the X chromosome. Pathogenic variants of the X-linked gene FLNA have been found in about half of patients with bilateral PVNH and in 100% of X-linked familial cases.
  • There is also a rarer form of bilateral PVNH that is caused by mutations of the ARFGEF2 gene. This gene is inherited in an autosomal recessive manner, in which the affected person has two copies of the abnormal gene, inheriting one from each parent, but parents are not affected.

Clinical history, physical exam and family history of seizures or malformation of cortical development is an important part of the evaluation.

Brain magnetic resonance imaging study (MRI) is the best imaging modality to evaluate PVNH and describe the extension and boundaries of brain malformation. It can also reveal any associated structural brain abnormality. MRI will show a clump of grey matter nerve cells that surround the ventricles and form nodules.

Figure: Brain MRI shows clumps of neurons near the brain's ventricles (arrows) typical for PVNH.

An EEG (electroencephalogram) is recommended if there are concerns that the patient is experiencing seizures. The EEG in children and adults with PVNH will likely show abnormal waveforms on either one side or both sides of the brain. Inpatient video EEG recording can be performed to characterize and localize the patient’s habitual seizures and can guide future treatment.

Magnetic resonance angiography (MRA) may also be recommended due to risk of stroke. Additional evaluations may be obtained when managing epilepsy in patients with drug-resistant seizures that are difficult to control with medications.

Antiseizure medications are used first to control seizures. Medications typically used for focal seizures include:

There is no evidence that one of these medications is more effective than another.

Epilepsy surgery may be an option for patients whose seizures are drug-resistant and is more likely to be a possibility for those with unilateral versus bilateral changes. Those who continue to have seizures despite trials of two or more antiseizure medications should be considered for referral to a Comprehensive Epilepsy Center. Seizures will be recorded by video EEG.

Some cases will be candidates for focal resection. Laser interstitial thermal therapy (LITT) or laser ablation is an emerging minimally invasive therapy and can be effective in a selective group of patients. Patients may require an invasive intracranial monitoring study to confirm the onset of seizures prior to surgical resection or ablation.

Dietary therapies can be an option for those in whom resective surgery is not possible, such as ketogenic diet, modified Atkins diet and low glycemic index diet.

Additionally, neurostimulation devices such as vagus nerve stimulation (VNS), responsive neurostimulation (RNS), and deep brain stimulation (DBS) can be considered in such cases.

Given the variety of treatment options, each case should be individually considered and discussed in a comprehensive epilepsy program for the best results.

What is the outlook for patients with PVNH?

The outlook for patients with PVNH is variable. Patients can present with infrequent seizures that are responsive to medications and normal development. Frequent drug-resistant seizures with intellectual disability can also occur in some cases.

Factors that can predict the outlook of PVNH include the location and extension of nodular heterotopias, seizure type and frequency, cognitive function, and response to anti-seizure medications. Long term follow-up visits with an epileptologist (epilepsy specialist) is typically recommended for the management of epilepsy associated with PVNH.

Authored By:

Abdulrahman Alwaki MD

on Friday, January 01, 2021

Reviewed By:

Epilepsy Foundation Communications
Omar A. Danoun MD

on Friday, January 01, 2021


Epilepsy Centers

Epilepsy centers provide you with a team of specialists to help you diagnose your epilepsy and explore treatment options.


Epilepsy Medication

Find in-depth information on anti-seizure medications so you know what to ask your doctor.


Epilepsy and Seizures 24/7 Helpline

Call our Epilepsy and Seizures 24/7 Helpline and talk with an epilepsy information specialist or submit a question online.


Tools & Resources

Get information, tips, and more to help you manage your epilepsy.


Find an Epilepsy Specialist

Ready for help? Find an Epilepsy specialist who can help guide you through your epilepsy journey.